These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 33991036)
1. The effects of infliximab in treating idiopathic inflammatory myopathies: A review article. Ge Y; Li S; Chen F; He L; Li C; Lu X; Wang G Dermatol Ther; 2021 Jul; 34(4):e14976. PubMed ID: 33991036 [TBL] [Abstract][Full Text] [Related]
5. Local injection of infliximab into calcinosis lesions in patients with juvenile dermatomyositis (JDM): a clinical trial. Shiari R; Khalili M; Zeinali V; Shashaani N; Samami M; Moghaddamemami FH Pediatr Rheumatol Online J; 2024 Jan; 22(1):2. PubMed ID: 38166943 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis. Zhen C; Hou Y; Zhao B; Ma X; Dai T; Yan C Front Immunol; 2022; 13():1051609. PubMed ID: 36578492 [TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients. Campanilho-Marques R; Deakin CT; Simou S; Papadopoulou C; Wedderburn LR; Pilkington CA; Arthritis Res Ther; 2020 Apr; 22(1):79. PubMed ID: 32293539 [TBL] [Abstract][Full Text] [Related]
8. Juvenile dermatomyositis associated with autoantibodies to small ubiquitin-like modifier activating enzyme: a report of 4 cases from North India and a review of literature. Vignesh P; Barman P; Basu S; Mondal S; Ishran B; Kumrah R; Dod A; Garg R; Rawat A; Singh S Immunol Res; 2023 Feb; 71(1):112-120. PubMed ID: 36278969 [TBL] [Abstract][Full Text] [Related]
9. Angioedema-like presentation as the presenting finding of juvenile myositis and juvenile dermatomyositis in 2 patients. Karaca Ö; Güngör M; Sakarya Güneş A; Eser Şimşek I; Anık Y; Kara B Int J Rheum Dis; 2022 May; 25(5):617-625. PubMed ID: 35238477 [TBL] [Abstract][Full Text] [Related]
10. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672 [TBL] [Abstract][Full Text] [Related]
11. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. Spencer CH; Rouster-Stevens K; Gewanter H; Syverson G; Modica R; Schmidt K; Emery H; Wallace C; Grevich S; Nanda K; Zhao YD; Shenoi S; Tarvin S; Hong S; Lindsley C; Weiss JE; Passo M; Ede K; Brown A; Ardalan K; Bernal W; Stoll ML; Lang B; Carrasco R; Agaiar C; Feller L; Bukulmez H; Vehe R; Kim H; Schmeling H; Gerstbacher D; Hoeltzel M; Eberhard B; Sundel R; Kim S; Huber AM; Patwardhan A; Pediatr Rheumatol Online J; 2017 Jun; 15(1):50. PubMed ID: 28610606 [TBL] [Abstract][Full Text] [Related]
12. Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management. Walling HW; Gerami P; Sontheimer RD Paediatr Drugs; 2010; 12(1):23-34. PubMed ID: 20034339 [TBL] [Abstract][Full Text] [Related]